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Abstract
Background—The intestinal microbiota has been implicated in the pathophysiology of Irritable
Bowel Syndrome (IBS). Due to the variable resolutions of techniques used to characterize the
intestinal microbiota, and the heterogeneity of IBS, the defined alterations of the IBS intestinal
microbiota are inconsistent. We analyzed the composition of the intestinal microbiota in a defined
subgroup of IBS patients (diarrhea-predominant IBS, D-IBS) using a technique that provides the
deepest characterization available for complex microbial communities.
Methods—Fecal DNA was isolated from 23 D-IBS patients and 23 healthy controls (HC).
Variable regions V1-V3 and V6 of the 16S rRNA gene were amplified from all samples. PCR
products were sequenced using 454 high throughput sequencing. The composition, diversity and
richness of microbial communities were determined and compared between D-IBS and HC using
the Quantitative Insights Into Microbial Ecology pipeline.
Key Results—The contribution of bacterial groups to the composition of the intestinal
microbiota differed between D-IBS and HC. D-IBS patients had significantly higher levels of
Enterobacteriaceae (p = 0.03), and lower levels of Fecalibacterium genera (p = 0.04) compared to
HC. β-diversity values demonstrated significantly lower levels of UniFrac distances in HC
compared to D-IBS patients. The richness of 16S rRNA sequences was significantly decreased in
D-IBS patients (p < 0.04).
Conclusions and Inferences—Our 16S rRNA sequence data demonstrates a community-level
dysbiosis in D-IBS. The altered composition of the intestinal microbiota in D-IBS is associated
with significant increases in detrimental and decreases in beneficial bacterial groups, and a
reduction in microbial richness.
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Background & Aims
Functional gastrointestinal disorders (FGID) are the most prevalent gastrointestinal disorders
(GI) in the US[1], and are associated with major patient disability[2], impaired quality of
life[3], and a significant economic burden[4]. Irritable Bowel Syndrome (IBS) is the most
common disorder among FGID[5], affecting 10-20% of adults and adolescents in the US[6].
Traditionally, IBS has been viewed as a disorder of altered intestinal motility and visceral
hypersensitivity, in which the clinical presentation and the severity of the symptoms can be
influenced by various psychosocial factors[7]. IBS can present as diarrhea, constipation, or
mixed bowel type predominant. Despite intensive research over the past two decades the
etiology of IBS remains poorly understood, thus leading to limited effective treatments for
patients with these disorders[8].
Animal and clinical human studies have provided evidence that the intestinal microbiota
plays an important role in maintaining normal GI function, and that alterations in the
composition of the intestinal microbial community can contribute to the development of
functional GI symptoms[9-13]. For example, it has been reported that altering the
composition of the intestinal microbiota with an antibiotic in mice can increases visceral
sensation and that this antibiotic-induced hypersensitivity can be reversed using a
probiotic[14]. Furthermore, studies show that manipulation of the intestinal microbiota in
humans with probiotics or antibiotics may be effective in alleviating IBS symptoms[15-18].
Several studies have shown differences in the composition of the microbiota between
patients with IBS and healthy controls. However, the results of these studies are not
consistent, and a consensus has not been reached regarding the specific differences in the
microbiota between clinically-defined IBS subgroups of patients and healthy controls[13,
19]. This can be partly ascribed to methodological biases, and limited depth of
characterization of complex microbial communities in the intestine. To better understand the
role of the intestinal microbiota in IBS we used high throughput 454 pyro-sequencing of the
16S rRNA gene to characterize the composition and diversity of the complex intestinal
microbial community in an unbiased manner[20-22]. Since IBS is a heterogeneous disorder,
and it is likely that differences in intestinal functions between different IBS subgroups may
further affect the composition of the intestinal microbiota, the current study specifically
focused on diarrhea-predominant IBS (D-IBS).
Methods and Methods
Study Population
We studied 23 patients that met the Rome III criteria for D-IBS and 23 healthy controls.
Subjects were recruited from the Chapel Hill general population and from the University of
North Carolina (UNC) healthcare outpatient clinics by advertising.
Inclusion criteria consisted of subjects that were 18 years or older, and of any gender, race,
or ethnicity. Healthy controls had no recurring GI symptoms. IBS subjects with a history of
GI tract surgery (other than appendectomy or cholecystectomy), a history of inflammatory
bowel diseases (IBD), celiac disease, lactose malabsorption, or any other diagnosis that
could explain chronic or recurring bowel symptoms were excluded from the study. In
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addition, participants were excluded if they had a history of treatment with antibiotics, anti-
inflammatory agents including aspirin, non-steroid anti-inflammatory drugs (NSAIDs or
steroids), or if they had intentionally consumed probiotics two months prior to the study. An
eight-week wash-out period was required for subjects who reported intentional consumption
of probiotics prior to enrollment. All subjects were evaluated by a physician to exclude an
alternative diagnosis to IBS. The study was approved by the UNC Internal Review Board
(IRB) and all subjects provided written consent prior to participation in the study.
Sample Collection and Preparation
Fresh stool samples were collected from all 46 subjects on site when possible during a single
study visit at UNC. Subjects unable to provide stool samples at the visit were instructed to
collect a specimen at home and return it to study staff at the same morning. Each fecal
sample was immediately transferred to the laboratory where it was homogenized, divided
into aliquots and stored at -80°C for future DNA isolation and molecular microbiological
analysis.
Isolation of DNA
Bacterial DNA was isolated from a total of 46 fecal samples (which included 37 samples
from our previously reported studies [healthy controls = 21, D-IBS = 16]) using a phenol/
chloroform extraction method combined with physical disruption of bacterial cells and a
DNA clean-up kit (Qiagen DNeasy® Blood and Tissue extraction kit [Qiagen, Valencia,
CA]) as previously described[23]. Briefly, 100 mg of frozen feces was suspended in 750 μl
of sterile bacterial lysis buffer (200 mM NaCl, 100 mM Tris [pH 8.0], 20 mM EDTA, 20 mg
mL-1 lysozyme) and incubated at 37°C for 30 min. Next, 40 μl of proteinase K (20 mg
mL-1) and 85 μl of 10% SDS was added to the mixture and incubated at 65°C for 30 min.
300 mg of 0.1 mm zirconium beads (BioSpec Products, Bartlesville, OK) was then added
and the mixture and homogenized in a bead beater (BioSpec Products, Bartlesville, OK) for
2 min. The homogenized mixture was cooled on ice and then centrifuged at 14,000 rpm for
5 min. The supernatant was transferred to a new 1.5 ml microfuge tube and fecal DNA was
further extracted by phenol/chloroform/iso-amyl alcohol (25:24:1) and then chloroform/iso-
amyl alcohol (24:1). Following extraction the supernatant was precipitated by absolute
ethanol at -20°C for 1 hour. The precipitated DNA was suspended in DNase free H2O and
then cleaned using the DNeasy® Blood and Tissue extraction kit (Qiagen, Valencia, CA)
from step 3 as per the manufacturer's instructions.
454 pyro-sequencing of 16S rRNA genes
Bacterial community composition in isolated DNA samples was characterized by
amplification of the V1-3 (forward, 8f:5′-AGAGTTTGATCMTGGCTCAG-3′; reverse
518r: 5′-ATTACCGCGGCTGCTGG-3′) and V6 (forward, 8f:5′-
AGGATTAGATACCCTGGTA-3′; reverse 518r: 5′-CRRCACGAGCTGACGAC-3′)
variable regions of the 16S rRNA gene by polymerase chain reaction (PCR). Forward
primers were tagged with 10 bp unique barcode labels at the 5′ end along with the adaptor
sequence (5′-CCATCTCATCCCTGCGTGTCTCCGACTCAG-3′) to allow multiple
samples to be included in a single 454 GS FLX Titanium sequencing plate as previously
described[24, 25]. 16S rRNA PCR products were quantified, pooled, and purified for the
sequencing reaction. 454 GS FLX Titanium sequencing was performed on a 454 Life
Sciences Genome Sequencer FLX machine (Roche, Florence, SC) at the microbiome core at
UNC-Chapel Hill (http://www.med.unc.edu/microbiome).
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Analysis of 16S rRNA sequences using the QIIME pipeline
16S rRNA sequence data generated by the 454 GS FLX Titanium sequencer was processed
by the quantitative insights into microbial ecology (QIIME) pipeline[26]. Briefly, sequences
that were less than 200 bp or greater than 1,000 bp in length, contained incorrect primer
sequences, or contained more than 1 ambiguous base were discarded. The remaining
sequences were assigned to D-IBS and HC groups based on their unique nucleotide
barcodes, including error-correction[24]. Chimeric sequences were removed using
ChimeraSlayer[27]. Sequences were clustered into Operational Taxonomic Units (OTUs)
based on their sequence similarity at 97% sequence similarity (similar to species level) using
UCLUST[28]. A representative sequence for each OTU was chosen for downstream
analysis based on the most abundant sequence from each OTU. PyNAST was used to align
sequences with a minimum length of 150 bp and a minimum percent identity of 75.0[29].
OTUs were assigned to a taxonomy using the Ribosomal Database Project (RDP) Naive
Bayes classifier[30]. The RDP classifies a 16S rRNA sequence based on Bergey's manual of
determinative bacteriology[31] (a main resource for determining bacterial species). A
bacterial group is designated as unclassified if the 16S rRNA gene sequence from an
organism does not show significant homology to any known classified bacterium in the
RDP. α-diversity (diversity within samples) was assessed and rarefaction curves were
generated for each experimental group. β-diversity (diversity between groups of samples)
was used to generate principal coordinate plots for each sample using un-weighted and
weighted UniFrac distances[32-34]. α- and β-diversity measurements were combined with
each group (D-IBS and HC) to produce visualizations (α-diversity - rarefaction plots; β-
diversity - Principal Co-ordinate Analysis [PCoA] plots, and OTU network plots) that allow
composition of the intestinal microbiota between groups to be readily interpreted. α-
rarefaction was used to measure the distribution of bacterial taxa richness in sample groups.
PCoA plots were used to visualize the similarities or dissimilarities of variables that best
represent the pair-wise distances between sample groups. An OTU network-based analysis
was used to visualize OTU sharing between sample groups where a bipartite network was
generated in which D-IBS and HC samples were designated as one node type, and bacterial
OTUs were designated as a second node type. A given sample was connected to a given
bacterial OTU node through a line (edge) if that OTU was detected in the subject.
Quantitative PCR
qPCR was performed using the SYBR ® Green PCR master mix (Applied Biosystems,
Carlsbad, CA) with primers that amplify the genes encoding 16S rRNA from
Faecaibacterium prausnitzii (forward, 5′-GATGGCCTCGCGTCCGATTAG-3′; reverse, 5′-
CCGAAGACCTTCTTCCTCC-3′) and all bacteria (forward, 5′-
GTGSTGCAYGGYTGTCGTCA-3′; reverse, 5′- ACGTCRTCCMCACCTTCCTC-3′).
qPCR assays were conducted in 96-well plates on an Eppendorf Realplex2 mastercycler
thermocycler (Eppendorf, Hauppauge, NY). Each PCR was carried out in a final volume of
25 μl and contained the following: 1 × SYBR green master mix, 0.5 μM of each primer and
10 ng of purified fecal DNA. PCR conditions were as follows: 10 min at 95°C, followed by
40 cycles of 95°C for 15 s, 20 s at 50°C, and 72°C for 1 min. Each plate included duplicate
reactions per DNA sample, the appropriate set of standards and a ‘no template’ negative
control for each primer set. qPCR standards were generated by PCR amplification of target
sequences from genomic DNA of an appropriate positive control strain. Analysis of melting
curves confirmed that the fluorescence signal originated from specific PCR products and not
from primer-dimers or other artifacts.
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Before statistical comparisons were made all data sets were assessed for normality using the
D'Agostino and Pearson omnibus normality test. When a data set was identified as not
having a normal distribution it was transformed by square root and retested for normality.
Data sets normally distributed were compared using a Student's t-test. All statistical
comparisons were carried out using GraphPad software (v4.0a; Prism, San Diego, CA). We
used taxon and phylogenetic-based analyses to compare the 16S rRNA gene sequences
between D-IBS patients and healthy controls. Taxon-based: The means and standard
deviations of abundances of bacterial groups (Phylum, Class, Order, Family, and genus)
were calculated and compared between D-IBS patients and healthy controls. A p value of
less than 0.05 was considered significant. Phylogenetic-based: Phylogenetic trees for D-IBS
patients and healthy controls were generated using the QIIME pipeline[26]. Each tree was
subjected to weighted and un-weighted UniFrac analysis[32-34] through the QIIME
pipeline. UniFrac distances represent the fraction of branch length that is shared by any two
samples' communities in a phylogenetic tree built from 16S rRNA sequence data from all
samples. A ‘weighted’ UniFrac analysis indicates microbiota community differences
between sample groups due to differences in relative taxon abundance, whereas an ‘un-
weighted’ UniFrac analysis indicates microbiota community differences between sample
groups based on the presence or absence of taxa[32-34]. UniFrac distances (weighted and
un-weighted) were compiled into matrices and average UniFac distances were calculated for
each group and compared using a student's t test. For qPCR the percentage of F. prausnitzii
was determined in all fecal samples ([copies 16S rRNA gene for F. prausnitzii/copies of 16S
rRNA gene for all bacteria] ×100). qPCR data was transformed to normality by square root
and means were compared using a Student's t-test.
Results
I. Study Population
A total of 46 subjects (D-IBS n=23, HC n=23) were investigated. All subjects provided fresh
fecal samples. The study population consisted of 76% females with a mean age of 34 years.
Demographics and body mass index (BMI) were similar in the two study groups (Table 1).
II. Characterization of the D-IBS and HC fecal microbiota
A total of 378,693 and 303,213 16S rRNA sequences with acceptable quality were obtained
from the V1-3 and V6 16S rRNA regions, respectively, with an average of 8,232 and 6,591
reads per sample (range: V1-3 2,939-19,305; V6 1,556-13,027). The number of sequence
reads did not significantly differ between D-IBS and HC groups. In order to determine the
number and abundances of different bacterial groups in each sample we used 3%
dissimilarity between 16S rRNA gene sequences as an indicator of a ‘genus level’ OTU.
Using this procedure, we found a total of 8,340 and 2,754 OTUs from the V1-3 and V6
regions, respectively, in samples obtained from the 46 subjects.
III. Contribution of bacterial taxa to the composition of the fecal microbiota
The abundance of different bacterial taxa identified by 16S rRNA V1-3 and V6 region OTU
sequence alignments were found to differ between D-IBS patients and HC (Figures 1 A&B
for V1-3 region, and supplementary figure S1 for V6 region). The levels of several specific
bacterial groups, ranging from Phylum to genus, were found to significantly differ between
D-IBS patients and HC (Table 2). V1-3 and V6 16S rRNA sequence analysis found that
unclassified Enterobacteriaceae (genus level) were significantly increased in D-IBS patients
when compared to HC. This significant increase was also observed in higher taxonomic
levels that encompass unclassified Enterobacteriaceae (Class – Gammaproteobacteria,
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Order – Enterobacteriales, Family – Enterobacteriaceae), indicating a structural shift in the
microbiota of D-IBS patients. This significant change was also found at the Phylum level
(Proteobacteria) with V6 16S rRNA sequences.
As shown in Figure 1C we found a significant 1.5 fold decrease in the Faecalibacterium
genus in D-IBS patients when compared to HC when analyzing V1-3 16S rRNA sequences.
A decrease (1.2 fold) in the Faecalibacterium genus in D-IBS patients was also observed
with V6 16S rRNA sequences, however this this not reach statistical significance (p = 0.41).
Thus, to validate the observation in V1-3 16S rRNA sequences we investigated the
concentration of the only known member of the Faecalibacterium genus (Faecalibacterium
prausnitzii) using qPCR. Our analysis found a significant 1.7 fold decrease (p = 0.05) in the
concentration of F. prausnitzii in samples from D-IBS patients when compared to HC
(Figure 1D).
IV. Differentiation of the Healthy and D-IBS intestinal microbiotas
To compare the global composition of the microbiota between D-IBS patients and HC we
used two different yet complementary methods. In the first approach weighted and un-
weighted UniFrac[32-34] distances between samples were calculated and compared. The
Principal Coordinate Analysis (PCoA) of weighted and un-weighted D-IBS patients and HC
UniFrac distances revealed an overlap between D-IBS and HC sample clusters. However,
comparison of average UniFrac distances from V6 16S rRNA sequences revealed a
significant decrease in HC samples when compared to the D-IBS group in both weighted
(D-IBS = 0.19, HC = 0.16, p = 0.01) and un-weighted (D-IBS = 0.58, HC = 0.55, p = 0.04)
analyses (Figure 2 A&B), indicating the microbiotas of HC are more similar to each other
when compared to D-IBS patients. A decrease in UniFrac distances were also observed with
V1-3 16S rRNA sequences, however these differences did not reach statistical significance
(weighted: D-IBS = 0.22, HC = 0.21, P = 0.25) and un-weighted (D-IBS = 0.74, HC = 0.73,
p = 0.25).
In our second approach a bipartite network of D-IBS and HC samples was generated. In
figure 3 D-IBS and HC samples are represented by one node type and bacterial OTUs are
designated as a second node type. If a sample from a particular group contains a specific
OTU they are connected via an ‘edge’ to create a pattern/network of shared OTUs. This
OTU network, based on V1-3 16S rRNA gene sequences, demonstrates that D-IBS patients
share more OTUs with other D-IBS patients than with HC; similarly HC subjects share more
OTUs with other HC subjects than with D-IBS patients (Figure 3). Analogous results were
found for V6 16S rRNA sequences (supplementary figure S2).
V. Bacterial richness in the intestinal microbiota
Bacterial richness was assessed by rarefraction of OTUs found in D-IBS and HC samples.
From 3,670 sampled sequences microbial richness was found to be significantly lower in D-
IBS patients when compared to HC (p < 0.04), based on the V1-3 16S rRNA variable region
(Figure 4). Microbial richness was slightly lower in D-IBS patients when compared to HC
based on the V6 16S rRNA variable region; however this reduction did not reach statistical
significance (Supplemental Figure 3). Although a relatively large number of 16S rRNA gene
sequence reads were generated from each sample, these rarefaction curves indicate that
species discovery is still increasing at this sequence depth. Thus, it is important to note that
differences between groups of organisms with abundance lower than 0.1% may not be
detected.
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In the current study we characterize and compare the fecal microbiota in a well-
characterized subgroup of patients with D-IBS and healthy controls using high throughput
454 pyro-sequencing of the 16S rRNA gene. The 16S rRNA gene contains nine variable
regions, all of which have been used to characterize complex microbial communities[35].
The depth of our analyses is strengthened by the investigation of four variable regions of the
16S rRNA gene (V1-3 and V6). We chose to investigate the V1-3 regions of the 16S rRNA
gene as it has been reported that combining variable regions to make longer sequences
(specifically V1-3) provides a more accurate resolution of the intestinal microbiota[36]. We
also chose to use the shorter V6 region of the 16S rRNA gene as it has been used previously
to investigate the intestinal microbiota[37], and also to provide comparative and
complementary data for the longer V1-3 region. Using this approach we investigated over
680,000 16S rRNA gene sequences with an average of over 8,000 and 6,500 sequences per
sample for the V1-3 and V6 regions, respectively. The results of our study indicate an
intestinal microbial dysbiosis in D-IBS patients, with alterations in specific bacterial groups
(ranging from genus to Phylum level), and microbial community diversity. Taxonomic
analysis revealed a significant increase in unclassified Enterobacteriaceae in D-IBS
patients. Unclassifed Enterobacteriaceae refers to bacterial genera encompassed by the
Enterobacteriaceae Family, yet little is known about this group or their function. The
Enterobacteriaceae Family contains thirty seven genera which include several pathogenic
bacteria such as; Escherichia, Shigella, Salmonella, and Yersinia. The significant increase of
unclassified Enterobacteriaceae in our D-IBS samples raised the possibility of recent
infection or a post-infections etiology (PI-IBS). However, none of our patients reported the
onset of IBS symptoms after intestinal infection (in response to specific question at
screening), and all our study subjects were screened for intestinal infections by routine stool
culture for intestinal pathogens. In regard to this, it should be noted that the
Enterobacteriaceae Family does not solely encompass pathogenic bacteria.
At the genus level, our study also found a significant reduction in the concentrations of the
Fecalibacterium genus in D-IBS patients when compared to healthy controls. Currently, it is
thought that the Faeclibacterium genus consists of one bacterial species; Faecalibacterium
prausnitzii, a major constituent of the Clostridium leptum group[38-40]. Interestingly,
reduced numbers of this organism has been shown in ileal Crohn's disease[41, 42],
suggesting protective and anti-inflammatory properties of this organism. Our finding of
reduced numbers of F. prausnitzii in patients with D-IBS further supports the possibility of
an inflammatory component in this condition. Given the finding of increased unclassified
Enterobacteriaceae and a reduction in the Faeclibacterium genus, it can be speculated that
the intestinal microbial dysbiosis in D-IBS is associated with an imbalance in the ratio of
detrimental and beneficial bacterial groups, a phenomenon also reported in inflammatory
bowel disease[20]. Our study used a deep and comprehensive sequencing approach to
characterize the intestinal microbiota, and as such we have identified additional bacterial
groups not yet reported as being altered in D-IBS compared to healthy controls. At the genus
level we found a significant increase in the concentration of Ethanoligenens in D-IBS
patients. Additionally, Enterococcus, Fusobacterium, Pediococcus, unclassified
Lactobacillaceae and Veilonella species were found in D-IBS patients but were below
detection limits in healthy controls. The biological relevance for these organisms and their
association with D-IBS remains to be determined.
Complex microbial communities are also typically compared based on their
biodiversity[43]. Changes in α-diversity (diversity within a sample) and β-diversity
(diversity between collections of samples) are important independent measures for complex
microbial communities. Diversity measures provide additional important information on the
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overall structure of intestinal microbial communities. Our study found a significant
reduction in α-diversity measurements (rarefaction analysis) in the fecal microbiota of D-
IBS patients suggesting that the fecal microbiota of D-IBS patients has lower microbial
richness. In addition, we found a significant reduction in β-diversity measurements (UniFrac
distance analysis) in the fecal microbiota of healthy controls indicating that the fecal
microbiotas in healthy controls are more similar to each other than to the fecal microbiotas
of D-IBS patients. Intestinal microbial richness is a result of co-evolution between host and
microbe [44], and has been shown to be stable over time in healthy individuals [45] and
reduced in disease conditions such as ileal Crohn's disease[20]. Thus, a departure from the
normal microbial richness of the intestinal microbiota may reflect a disease, possibly
inflammatory, state in D-IBS. Given the significant differences in bacterial taxa and α- and
β-diversity measurements between the microbiotas in D-IBS patients and healthy controls, it
can be speculated that a microbial intestinal dysbiosis exists in D-IBS patients that is a result
of the increase or decrease in specific bacterial groups and changes in the global structure of
the intestinal microbiota[34].
Previous studies have investigated the intestinal microbiota in patients with IBS and
reported various alterations in specific bacterial groups[46-50], changes in fingerprint
patterns[23, 49, 51-54], and global compositional differences in the microbiota based on
clone libraries[55, 56]. However, many of these studies have used molecular techniques that
provide a limited resolution of complex intestinal microbial communities. Two recently
published studies have used advanced molecular techniques based on the 16S rRNA gene
that provide deep characterization of the intestinal microbiota in IBS patients and healthy
controls. In the first study Saulnier et al.[57] used high throughput sequencing of the 16S
rRNA gene to characterize the microbiota in a mixed group of 22 children with IBS and 22
healthy controls. Differences in specific bacterial taxa were reported between the groups
suggesting an intestinal microbial dysbiosis in pediatric patients with IBS. γ-proteobacteria
were found to be increased in the microbiota of IBS patients, and a novel Ruminococcus-like
microbe was also enriched pediatric patients with this disorder. The study population from
this report significantly differed to our population as we investigated adult patients with a
defined sub-group of D-IBS. In the second study Rajilić-Stojanović et al.[58] used a 16S
rRNA gene microarray (the Human Intestinal Tract Chip – HITChip) to compare the
intestinal microbiotas between a mixed group of adult IBS patients (n=62) and healthy
controls (n=46). Interestingly, consistent with our finding, this group also reported a
significant decrease in the Faeclibacterium genus in their IBS patients. Similarly to the
Saulnier et al.[57] study, our current study differs from this report as it focuses on a specific
subgroup of IBS patients. Our decision to focus on a single subgroup of patients with D-IBS
was based on the assumption that differences in bowel habits (e.g., diarrhea and
constipation) could potentially mask differences in the levels of bacterial taxa and diversity
between specific subtype of IBS and healthy controls.
Our analyses the V1-3 and V6 regions of the 16S rRNA gene yielded different and
complementary results. For example, our sequence data found a significant increase in
unclassified Enterobacteriaceae with both V1-3 and V6 regions of the 16S rRNA gene. In
contrast, the V1-3 region found that the Fecalibacterium genus was significantly reduced in
D-IBS patients; however a decrease in the Fecalibacterium genus was also found for
sequences from the V6 region that did not reach statistical significance. Additionally, a
significant decrease in average weighted and un-weighted UniFrac distances was found
when analyzing the V6 16S rRNA region in healthy controls. A decrease in average
weighted and un-weighted UniFrac distances was also found when analyzing the V1-3 16S
rRNA region in healthy controls; however this did not reach statistical significance. Thus,
based on our sequence data investigation of four variable 16S rRNA regions has provided a
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detailed and comprehensive view of the fecal microbiota in patients with D-IBS and its
differences from the microbiota in healthy individuals.
Our study investigates fecal material to represent the intestinal microbiota in D-IBS patients
and healthy controls. However, it is important to note that the fecal and mucosal-associated
microbiota differ in composition and diversity[23, 59, 60]. Using the terminal-restriction
fragment length polymorphism (T-RFLP) fingerprinting technique we have recently
demonstrated compositional differences in both, fecal- and mucosal-associated microbiota
between patients with D-IBS and healthy controls. Thus, emphasizing the importance of
investigating both of these intestinal niches in this disorder[23].
In conclusion, we report an intestinal dysbiosis in D-IBS patients that is a result of
taxonomic, structural, and diversity differences in the intestinal microbiota in these patients
when compared to healthy controls. Furthermore, the findings of our taxonomic analysis
indicating higher levels of Enterobacteriaceae Family and lower levels of Faecalibacterium
prausnitzii suggests that the intestinal ‘dysbiosis’ in D-IBS may be associated with an
imbalance in the ratio of detrimental and beneficial intestinal bacteria. Although our study
does not answer the question of causality or confirm an etiological role for the altered
microbiota in this disorder, our study findings emphasizes the importance and provides the
rationale for further investigation of the role of the intestinal microbiota in the pathogenesis
of IBS. Future studies will need to address the association between intestinal functions (such
as motility) and the gut microbiota, and how these factors influence IBS symptoms. This
investigation will advance our understanding of the disorder and lead to new therapeutic
options for patients with functional bowel disorders.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Percent contribution of bacterial genera, identified by 454 pyro-sequencing of the V1-3 16S
rRNA gene region, to the fecal microbiota in (A) healthy controls, and (B) D-IBS patients.
(C) Average abundance of the Faecalibacterium genus in fecal samples from D-IBS patients
and healthy controls, based on V1-3 454 pyro-sequencing data. (D) Concentrations of
Faecalibacterium prausnitzii in the fecal microbiota of D-IBS patients and healthy controls
using qPCR. Statistical comparisons were carried out on the square root means of each
group.
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Variation in bacterial community composition between D-IBS patients and healthy controls.
A significant decrease in average UniFrac distances was found in healthy controls when
compared to the D-IBS group using weighted (A) and un-weighted (B) values for the V6
16S rRNA. All analyses represent the relationship between the microbiota in D-IBS and
healthy control in fecal samples based on their β-diversity. Statistical comparisons were
carried out on the square root means of each group.
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Operational Taxonomic Unit (OTU) network analysis of bacterial communities from D-IBS
patient and healthy control fecal samples for the V1-3 16S rRNA region. Nodes represent
individual D-IBS samples (red circles), individual healthy control samples (green circles),
and OTUs (white circles). Edges (lines) connecting D-IBS nodes (red edges) or healthy
control nodes (green edges) to OTUs indicate whether a given OTU was found in that
sample. The pattern of green and red edges indicates that although both groups share
common OTUs, D-IBS samples share more OTUs in common and segregate from healthy
control shared OTUs.
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Rarefaction curves of D-IBS (broken line) patient and healthy control (solid line) fecal
samples. Curves are based on α-diversity within sample groups for the V1-3 16S rRNA
region.
*Indicates significant differences between groups (p < 0.04). Statistical comparisons were
carried out on the square root means of each group.
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Table 1
Characteristics of D-IBS patients and healthy controls
D-IBS patients Healthy Controls
Number of subjects 23 23
Age (yr): mean (range) 35 (23-70) 34 (21-58)
% Female: 74 78
BMI (kg/m2): mean (range) 29 (18.7-43.8) 25 (18.1-40.5)
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